In recent years, the pharmaceutical logistics industry has reached a turning point. While the distribution of pharmaceutical products has increased significantly, the capacity for temperature-controlled logistics has become significantly tighter. Due to customs delays, many cargoes were held up in transit areas that lacked proper environmental controls, while others were forced to pass through general purpose cargo terminals because the necessary specialized infrastructure did not exist. As a result, the system has worked, but it has created tangible costs, resulting in approximately $38 billion in logistics and trade losses each year.
As a result, industry leaders are beginning to confront long-standing vulnerabilities that were previously accepted as inevitable, such as fragmented temperature control models, multi-legged routes, and storage environments not optimized for sensitive and high-value pharmaceuticals. Under everyday conditions, these gaps create inefficiencies. Under stress and emergency situations, they become systemic risks.
While many logistics providers are adapting their existing networks to meet pharmaceutical requirements, Frontier Scientific Solutions was designed from the beginning around how temperature-sensitive pharmaceuticals can be stored, handled, and transported as a single, controlled system.
The power of dedicated infrastructure
To address the major challenges facing the industry, leading companies are moving to dedicated pharmaceutical infrastructure that minimizes handoffs and reduces environmental fluctuations that can compromise product integrity. Frontier Scientific Solutions, headquartered in Wilmington, North Carolina, is a pioneer in this change. The company is intentionally designed to remove structural points of failure by placing only pharmaceutical handling at the center of its operating model, with a focus on direct shipping routes, cGMP-grade storage, reduced touchpoints, and engineered redundancies that maintain consistency across transportation.
When temperature-controlled materials are moved between fewer facilities, the potential for drift, mishandling, or delays is greatly reduced. Excursion risks are further reduced if these facilities are cGMP compliant and supported by advanced environmental monitoring systems.
By designing storage environments to tightly control temperature, residence time, and delivery conditions, Frontier reduces exposure before products enter transportation, allowing them to maintain product integrity rather than managing preventable risks in downstream transportation.
Frontier’s design philosophy integrates dedicated storage, advanced building management systems, and continuous environmental monitoring into a global gateway model that reflects the level of control required for sensitive medicines such as advanced biologics and cell and gene therapies.
Utilizing strategic temperature control gateways
With customs delays becoming one of the most significant bottlenecks in global pharmaceutical distribution, operating through congestion-free gateways is becoming increasingly important. Frontier Scientific Solutions operates two strategic locations in Wilmington, USA, and Shannon, Ireland, creating a transatlantic gateway between North America and Europe that supports fully temperature-controlled pharmaceutical storage and direct airside access.
Both locations take advantage of the Foreign Trade Zone (FTZ) designation, which allows for streamlined customs clearance, deferral of duties, and more predictable movement of sensitive materials. By combining cGMP-controlled storage directly with airside access on these gateways, Frontier minimizes idle dwell time and uncontrolled staging, two of the most common sources of temperature risk before loading begins. These features help the industry avoid long ground delays. In these cases, products traditionally spent more time waiting in an uncontrolled environment than they did in transit.
Fewer touch points, less risk
Another major evolution in pharmaceutical logistics is the move towards simpler and more direct global movement. Traditional models often route packages through multiple cargo hubs, resulting in handoffs and environmental exposure. Frontier Scientific Solutions’ direct and exclusive air service between the United States and Europe reduces touchpoints by approximately 75%, provides approximately 89% faster transportation at critical stages of the journey, and provides a more controlled end-to-end supply chain while keeping patients top of mind.
This level of simplicity is possible because the storage design, handoff process, and transport prioritization are designed together to allow products to move directly from a managed environment to dedicated transit, rather than through a tiered general-purpose network. These direct routes not only reduce risk but also reduce overall carbon impact by minimizing unnecessary handling and residence time.
Building solutions for the future
While logistics providers have made significant advances in recent years, much of the change has been gradual. Frontier Scientific Solutions represents a more fundamental shift in alignment with today’s scientific, regulatory, and operational realities. The company’s model provides a blueprint for what a redesigned pharmaceutical supply chain could look like, including fewer touchpoints, stronger environmental controls, simplified customs clearance, and strategically located global gateways designed for direct distribution.
The core of this approach reflects a move towards end-to-end product integrity, where risks are engineered across storage, handling and transportation rather than being managed reactively. For leaders across the pharmaceutical supply chain, there is a clear opportunity to build more reliable, predictable, and more secure networks at the moments that matter most. Given what’s at stake for patients, that’s the way forward.
